Introduction
Sleep disordered breathing (SDB) occurs in more than seven out of ten chronic heart failure (CHF) patients in New York Heart Association (NYHA) class >II, when using an apnoea hypopnoea index (AHI) >5/h. 1 Patients with CHF and SDB often report disturbed sleep and wake patterns with shorter total sleep time, markedly reduced sleep efficiency, as well as longer sleep onset latency and longer wake time after sleep onset compared to patients without SDB. 2 Other consequences include insomnia (i.e., difficulties initiating sleep, difficulties maintaining sleep and non-restorative sleep) and excessive daytime sleepiness. 3, 4 Sleep loss and sleep fragmentation are in other contexts known to affect cognitive functions such as memory encoding, consolidation, plasticity and reconsolidation. 5 Furthermore, executive functions, including decision-making processes 6 , as well as attention and psychomotor speed are also affected. 7, 8 It has been described that elderly individuals with mild to moderate CHF often have a mild cognitive dysfunction. 9 Recent studies 8, 10, 11 in adults (mean age 62.8 yrs) with cardiovascular disease show that "poor sleep" (i.e., global score ≥5 on the Pittsburgh Sleep Quality Index) is independently associated with reduced global cognitive function 10 and executive functioning and attention 11 . Other studies 12, 13, 14 not focusing on CHF show that SDB-related hypoxia can be an indicator associated with cognitive dysfunction and dementia. Furthermore, reduced quality of life, anxiety and depression have also been described. 15, 11 Sleep disturbances, such as SDB, may from a pathophysiological perspective affect the development of early atherosclerosis (i.e., by an increased sympathetic activation), and as a consequence increase the risk of vascular dementia in patients with CHF. 16 However, few if any studies have investigated the effects of SDB, insomnia and sleep-wake patterns on cognitive function in patients with CHF. The aim of the study was (I) to describe sleep and wake patterns, insomnia, excessive daytime sleepiness and cognitive function in community dwelling CHF patients with and without SDB and (II) to investigate the association between sleep-related factors and cognitive dysfunction.
Methods

Design and setting
This study has a cross-sectional design. A total of 137 stable consecutive patients with CHF living in the community were recruited after discharge from outpatient clinics at one university hospital and two county hospitals in the south of Sweden. Inclusion criteria were being 18 years of age and suffering from CHF, based on the European Society of Cardiology guidelines. 17 Exclusion criteria were severe psychiatric illness, a history of neurological disorders (e.g., Alzheimer´s disease, vascular or mixed dementia and severe head injury), drug abuse or difficulties reading and understanding the Swedish language. No patients within nursing homes or advanced home care were included.
Procedures
Demographic and clinical variables such as age, gender, marital status, cardiac function, medications, laboratory data and co-morbidities were collected by a study nurse during a clinical examination and from medical records. Laboratory data included erythrocytes, erythrocyte volume fraction, hemoglobin, leucocytes, thrombocytes, sodium, potassium, creatinine, albumin, transferrin, transthyretin, and B-type natriuretic peptide (BNP). CHF was classified with NYHA class II-IV. Diabetes diagnoses were based on a history of diabetes, and/or current treatment (oral therapy or insulin). Hypertension diagnoses were based on a blood pressure level of more than 140/90 mmHg. During the week that followed, patients answered questionnaires and performed registrations of SDB and sleep-wake pattern. After one week, a specialist educated/trained nurse performed the cognitive tests in the patients' homes or at the hospital. All data were collected between September 2009 and December 2011. The study was approved by the Ethics Committee (study code M222-08/T81-09) and conducted in accordance with the Declaration of Helsinki.
Measurements
Sleep and breathing
3:1. Sleep disordered breathing
Full night respiratory recordings were performed in the patients' homes using a portable twochannel screening tool (ApneaLink device, ResMed Corporation, Poway, CA, USA).
ApneaLink measures airflow through a nasal cannula connected to a pressure transducer and pulse oximetry. Apnoeas and hypopneas are automatically scored by the ApneaLink software and an AHI is provided based on recording time. Validation of the ApneaLink demonstrates that the device provides reliable information regarding AHI, when compared with a full polysomnography. 18 19 SDB was dichotomized into two groups; no SDB (AHI <15/hour of sleep) and SDB (AHI >15/hour of sleep).
Sleep and wake pattern
A one-week registration of the patients´ sleep and wake pattern was performed using actigraphy (SenseWear BMS Pro 2, BodyMedia Inc, Pittsburg, PA, USA The patients grade their difficulties on a scale ranging from no problems (0), to very great problems (4) . Using a summation score, insomnia can be sub-grouped as no insomnia (0-3), subclinical insomnia (4-6), moderate insomnia (7-9) and severe insomnia (10) (11) (12) . Results have shown that MISS possesses adequate reliability and validity among the elderly. 25 
Cognitive function
A battery of six well validated tests was used to measure different aspects of cognitive function.
Global cognitive function was measured with Mini-Mental State Examination (MMSE).
This is a cognitive screening test with a maximum score of 30. Examinees are not told beforehand that they will be asked to draw the figure from memory, since the immediate and delayed recall conditions are a test of incidental or implicit memory. 
3.4.5
The Memory of a story test was used for measuring episodic memory. A predetermined short story is read and the number of points is based on immediate (strict and liberal) or delayed (strict and liberal) response with a total of 21 points for each section. After 20 minutes the same test is performed again to test the recall of the same story. 31 
Spatial performance was measured with the Block Design test. The test measures
difficulties in copying designs, making constructions and matching or discriminating patterns or faces. 32 The participants have to use the blocks to reproduce seven patterns as quickly as possible. Each pattern has a maximum score from 2-7 and the summated score can therefore range between 0 and 51. 33 
Depression
Patient Health Questionnaire
The Patient Health Questionnaire (PHQ-9) is based directly on the Diagnostic and Statistical
Manual Fourth Edition (DSM-IV). It grades how often patients have been bothered by
problems related to depression during the last 2 weeks. 34 A scale ranging from not at all (0), to nearly every day (3) is used. PHQ-9 can be sub-grouped into no need of treatment for depression (0-4), mild depression (5-9), moderate depression (10) (11) (12) (13) (14) , moderate to severe depression (15) (16) (17) (18) (19) , and severe depression (20) (21) (22) (23) (24) (25) (26) (27) . The PHQ-9 and has showed good diagnostic validity. 34 
Co-morbidities
The Charlson comorbidity index was used for classifying co-morbidity. Nineteen co-morbid conditions were divided into 4 groups with weighted scores as follows: the first group included myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer and chronic liver disease (assigned weight 1). The second group included hemiplegia, moderate or severe kidney disease, diabetes, diabetes with complication, tumor, leukemia, lymphoma (assigned weight 2). The third group included moderate or severe liver disease (assigned weight 3), and the fourth group included malignant tumor, metastasis, AIDS (assigned weight 6). The index score is the total of the assigned weights based on 1 -year mortality. The index has demonstrated satisfactory measurement properties with acceptable test-retest reliability. 35 
Statistics
Descriptive statistics were used to describe the study population. Continuous data were described with median and quartiles. Categorical data were described as frequencies and percentages. Differences between the groups were tested with Mann-Whitney U test as data were not normally distributed. Categorical data were analyzed with Pearson's chi-square test.
As the assumption of normality was violated, multiple linear regression analyses with robust standard errors were conducted to investigate if SDB and insomnia were associated with cognitive functioning. 36 The cognitive tests were included as dependent variables while AHI, lowest saturation, saturation time below 90%, insomnia and daytime sleepiness were included as independent variables. To adjust for other variables related to cognitive functioning, sex (male), age, education (university degree), Body Mass Index (BMI), B-type natriuretic peptide (BNP), diabetes and smoking were included as covariates, since they have previously been found to affect cognition. A power analysis based on α= .05, 1-ß= 0.9, f2= .35 and 11
independent variables showed that a sample size of 72 participants should be sufficient for the regression models. According to variance inflation factor, depression had a linear relationship to insomnia (VIF=2.1) and was therefore removed from the regression model.
No other variables indicated problems with multicollinearity (VIF<2)
. A p-value of ≤ .05 was considered statistically significant. SPSS version 20.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analyses.
Results
Population
A total of 137 patients (68% male, median age 72 years, 58% NYHA II) were included in the study. Table 1 shows sample characteristics for the participants. Patients with SDB were older (p≤ .005), had worse functional capacity (i.e., scored in a higher NYHA class) (p≤ .022) had more atrial fibrillation (p≤ .001), higher creatinine values (p≤ .001) and used more diuretics (p≤ .03) compared to patients without SDB. The Charlson co-morbidity index showed no significant differences between those with and without SDB, and the low index mean value showed low risk for 1-year mortality in both groups. Patients with missing ApneaLink data (n=30) were older (p≤ .031), had higher creatinine values (p≤ .016) and used less B-blockers (p≤ .024) compared to those with full ApneaLink data (n=107). None of the patients had documented or treated OSA or used continuous airway pressure ventilation therapy before study inclusion. (42) 14 (30) .239
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Cognitive function
According to the MMSE seventy-eight percent of the whole study population had normal global cognitive function, 18% had mild cognitive dysfunction and 4% suffered risk of dementia ( Table 3) .
Measures of psychomotor speed, executive functions, visual-spatial perception/construct and memory, semantic and episodic memory and spatial abilities showed no differences between those with and without SDB. Patients with missing ApneaLink data (n=30) had a significantly lower performance in semantic (p< .001) and spatial memory (p< .05). 
Association between sleep and cognitive functioning
The regression analysis showed that insomnia was significantly associated with decreased global cognitive dysfunction (p< .05) ( 
Discussion
This study examines the effects of SDB and sleep and wake pattern on cognitive impairment with an extensive neuropsychological test battery among elderly patients with CHF living in the community. The majority of the patients in our study population had mild to moderate CHF and almost half of them had SDB. An important finding was that the cognitive function seemed to be rather well preserved in these CHF patients, irrespective of whether SDB occurred or not. Surprisingly, we only found minor associations between SDB and cognitive function.
The SDB prevalence of 44% in our study is comparable to the 51% (i.e., AHI>15 in patients with LVEF≤40%) and the 48% found by Oldenburg et al. 1 and Damy et al., 37 respectively.
SDB-related breathing events have in previous studies been found to cause a disturbed sleep structure with increased arousals, 38 insomnia, 39 and daytime sleepiness. 3 We found that patients with SDB had more difficulties maintaining sleep compared to those without SDB (76% vs. 60%, p< .05), but sleep and wake pattern, as well as insomnia variables, did not differ between the groups. Excessive daytime sleepiness was even more common among those without SDB (45% vs. 38%, p< .01) and in the older group with missing ApneaLink data (n=30). One explanation for this slightly surprising finding might be that SDB does not always present daytime symptoms. 38 Furthermore, insomnia in patients with CHF might be caused by other disturbances than SDB, such as anxiety, dyspnea, dysrhythmias, coughing, deteriorations and side-effects. 11, 40 The sensitivity of the ESS might be low since CHF-related fatigue can be interpreted as excessive daytime sleepiness. An objective method to evaluate daytime sleepiness (i.e., Multiple Sleep Latency Test) could therefore be a more valid measure. 41 Mild and severe global cognitive impairment, as measured with the MMSE, was found in 18% and 4% of the total sample, respectively, but no differences were identified between those with and without SDB. Neither did measurements of psychomotor speed, executive functions, visual-spatial perception/construct and memory, semantic and episodic memory and spatial abilities. A recent study investigating sleep apnoea (i.e., diagnoses derived from medical records) and cognitive function in elderly heart failure patients found that co-morbid sleep may constitute a great risk for cognitive impairment (i.e., attention and executive functions). 8 Other studies have found some type of cognitive impairment to occur among 25-80% of patients with CHF 9,13 and SDB can be important with regards to attention, memory, executive functions and psychomotor speed. 13, 14 The mechanism for this is based on the hypothesis that apnoeic events 13 and hypoxia 12, 14 following breathing events (i.e. apnoeas),
are associated with sympathetic activation causing increased blood pressure, especially in patients with obstructive sleep apnoea. 42 This might be of importance to the development of vascular dementia over time. We did not, despite the relatively high prevalence of SDB, find any significant associations between any SDB parameters and cognitive impairment.
However, patients with missing ApneaLink data (n=30) were older, had worse semantic memory and lower spatial performance compared to those with full ApneaLink data.
Inversely, their cognitive deficits could be an explanation for the missing data. When examining an elderly population (i.e., mean age 65 years) with different co-morbidities (i.e., arthritis, high blood pressure, diabetes, renal disease, asthma and liver disease), Cohen-Zion 43 found that only those with daytime sleepiness suffered from cognitive impairment. One explanation for the lack of association in the present study might be related to a potential referral bias. We included community-dwelling CHF patients who had been discharged from outpatient clinics. The Charlson co-morbidity index indicated that our sample had relatively few co-morbidities and, furthermore, there were no differences between those with and without SDB. Another explanation might be the relatively low number of patients suffering from deep desaturations and time below saturation <90%. Daytime sleepiness was also more common among those without SDB.
Insomnia may also affect memory and the ability to concentrate. 44, 45 The regression analyses showed that insomnia was associated with decreased global cognition. Higher age was associated with decreased executive function, visual-spatial perception and spatial performance. Higher education levels were important for improving global cognitive function and semantic memory, whereas smoking was related to impaired semantic and episodic memory. This is in line with previous findings in studies focusing on the elderly with and without cardiovascular disease. 10, 9, 13 Depression is a factor commonly discussed to have an impact on both normal sleep and cognitive function. A recent study 46 on community-dwelling older adults found, when using structural equation modeling, that cardiopulmonary symptoms (i.e., dyspnea, palpitations) and pain were directly associated with sleep disturbances, which led to an indirect association to depressive symptoms. Another recent study 47 found that impaired cardiac function was associated with both inflammation and a symptom cluster describing sickness behavior (i.e., anhedonia, fatigue, and sleepiness). However, none of these studies measured cognitive function. In the present study depression was removed from the regression model since it had a linear relationship to insomnia, but in clinical situations it should be considered as a factor of importance for cognitive dysfunction.
It is possible to elaborate on our findings that cognitive function is well-preserved in elderly patients with mild to moderate CHF, without extensive co-or multi morbidity. There were no associations between SDB and cognitive function. These findings might decrease worries among health care personnel that SDB and cognitive problems are significant clinical problems among patients in NYHA class II with few co-morbidities.
The design of the study was cross-sectional which limits the possibility to determine the causal effect between sleep disorders and cognitive dysfunction among the patients.
ApneaLink was used to collect data regarding SDB since it is a validated, 18, 19, 44 feasible tool that is easy to use for elderly patients in home based settings. However, limitations include that it is not extensively used in CHF studies, it lacks the possibility to distinguish between obstructive and central sleep apnoea, as well as determine sleep onset and awakenings. A more advanced recording device (i.e., with six or more channels) could have provided more detailed information about these aspects, but since it would have been more complicated to use for an elderly patient it may have increased the level of missing data even more. On the other hand, an extensive test battery was used to measure cognitive function. This enabled us to measure different aspects of cognitive function but it might have caused an increased number of missing data. Despite a large proportion of missing ApneaLink data (i.e., due to patients having problems using the device and/or due to fatigue, and/or unwillingness to perform the recording), the sample size for all regression models was higher than the a priori estimated sample size of n=72. The sample size can therefore be judged as sufficient. Patients with missing data were more fatigued. Future studies should have a prospective, longitudinal design including elderly-elderly patients with more severe heart failure and more comorbidity.
Conclusion
The prevalence of cognitive dysfunction was low in this population with predominantly mild to moderate CHF of which 78 % had a normal cognitive function. Almost half of the patients with CHF suffered from SDB. Difficulties maintaining sleep and excessive daytime sleepiness were associated with SDB. Insomnia was the only sleep-related factor significantly influencing cognition with more insomnia being related to poorer global cognitive function.
